Similar articles

• [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].

  Goepel M. Goepel M. Urologe A. 2006 Jul;45(7):847-51. doi: 10.1007/s00120-006-1121-8. Urologe A. 2006. PMID: 16816976 German. No abstract available.
• Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.

  Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group. Chapple CR, et al. BJU Int. 2004 Feb;93(3):303-10. doi: 10.1111/j.1464-410x.2004.04606.x. BJU Int. 2004. PMID: 14764127 Clinical Trial.
• Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.

  Hart WM, Abrams P, Munro V, Retsa P, Nazir J. Hart WM, et al. J Med Econ. 2013 Oct;16(10):1246-54. doi: 10.3111/13696998.2013.829079. Epub 2013 Sep 11. J Med Econ. 2013. PMID: 23885660
• Solifenacin for overactive bladder: a systematic review and meta-analysis.

  Luo D, Liu L, Han P, Wei Q, Shen H. Luo D, et al. Int Urogynecol J. 2012 Aug;23(8):983-91. doi: 10.1007/s00192-011-1641-7. Epub 2012 Feb 7. Int Urogynecol J. 2012. PMID: 22310924
• Tolterodine for the treatment of overactive bladder.

  Salvatore S, Serati M, Bolis P. Salvatore S, et al. Expert Opin Pharmacother. 2008 May;9(7):1249-55. doi: 10.1517/14656566.9.7.1249. Expert Opin Pharmacother. 2008. PMID: 18422481 Review.